All in all, the ephrin-B2-Fc treatment seems to exclusively exhibit EPHB4-mediated anti-BC effects, whereas berberine inhibits BC cell growth and migration by selective ephrin-B2 targeting. The gene discussed is EPHB4; the disease is breast cancer.